Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
ConditionProstate Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorHackensack Meridian Health
About this trial
To evaluate the effectiveness of a PSMA-PET scan in identifying recurrent prostate cancer after focal therapy
Eligibility criteria
Qualifiers
Adult males 18 years or older;
Patient must have a pre-treatment MRI;
Patient underwent SOC focal therapy with either focal or hemiablation for the treatment of intermediate risk prostate cancer in the past 9 months prior to enrollment;
Intermediate risk disease as defined by American Urology Academy (AUA)/National Comprehensive Cancer Network (NCCN) guidelines (see Appendix A)
Disqualifiers
Patients under the age of 18 will be considered pediatric patients and will not be included in this study because they are thought to represent a unique population outside the scope of this study as it is aimed at identifying factors that affect adults only.
Patients previously treated with whole gland ablation or prior partial gland ablation over 9 months prior to enrollment.
Trial design
Treatments tested in this trial
- 18F-rhPSMA-7.3
Treatment groups
70 Participants
are divided into 1 treatment groupSponsors and collaborators
Hackensack Meridian Health
Lead sponsor
Blue Earth Diagnostics
Collaborator
Source ClinicalTrials.gov